Health Fair 11 at the Fair Offers Healthy Options to State Fair Goers
August 15, 2019 17:35 ET
|
Minnesota Health Fairs Inc.
GOLDEN VALLEY, Minn., Aug. 15, 2019 (GLOBE NEWSWIRE) -- The Minnesota State Fair is all about tradition. Fairgoers have their must-eat food(s!), their tried-and-true route around the fairgrounds,...
Food Allergies Are Top Concern for Families As They Prepare for Back-to-School
August 15, 2019 08:21 ET
|
Asthma and Allergy Foundation of America
Washington, D.C., Aug. 15, 2019 (GLOBE NEWSWIRE) -- Today, the Asthma and Allergy Foundation of America (AAFA) released a report of findings from its “My Life With Food Allergy” study. As children...
Intrommune Therapeutics Receives Best Private Company Presentation Award at BioNJ’s 9th Annual BioPartnering Conference
May 17, 2019 13:25 ET
|
Intrommune Therapeutics
New York, May 17, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing patient-friendly food allergy therapies for peanut and other food allergies...
Quick Umbrellux DAO Test Reveals If That Reaction Is Really Histamine Intolerance And Not A Food Allergy
May 13, 2019 09:30 ET
|
Umbrellux DAO
ANN ARBOR, Mich., May 13, 2019 (GLOBE NEWSWIRE) -- Food Allergy Awareness Week is the perfect time to determine if you may be mislabeling your body’s reaction to certain foods. Umbrellux DAO offers...
Intrommune Therapeutics Announces Grant of European Patent Covering Oral Mucosal Immunotherapy for Food Allergy
March 08, 2019 10:01 ET
|
Intrommune Therapeutics
New York, March 08, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, is...
US BioTek Laboratories Announces Jack Frausing as CEO
January 14, 2019 08:00 ET
|
US BioTek
SEATTLE, Jan. 14, 2019 (GLOBE NEWSWIRE) -- US BioTek Laboratories (US BioTek) announced today the appointment of a new President and CEO, Jack Frausing. Frausing assumes the leadership from...
Intrommune Therapeutics Announces First Close of Series A Preferred Equity Financing and Successful Close of Crowdfunding Financing Campaign to Support New Peanut Allergy Treatment
November 08, 2018 16:44 ET
|
Intrommune Therapeutics
New York, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, is...
Intrommune Therapeutics Completes Pre-IND Meeting With FDA on INT301 for Peanut Allergy
September 06, 2018 07:11 ET
|
Intrommune Therapeutics
New York, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biopharmaceutical company developing a patient-friendly immunotherapy platform for the treatment of food...
Intrommune Therapeutics Submits Pre-IND Meeting Request to the U.S. FDA for INT301, Its Peanut Allergy Oral Mucosal Immunotherapy Drug Candidate, During Food Allergy Awareness Week
May 15, 2018 12:00 ET
|
Intrommune Therapeutics
New York, May 15, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a NYC-based biopharmaceutical company developing a patient-friendly immunotherapy platform for the treatment of food...
Intrommune Therapeutics Announces Crowdfunding Financing Campaign to Support Food Allergy Treatment Research
May 09, 2018 10:36 ET
|
Intrommune Therapeutics
New York, May 09, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics is pleased to announce the launch of a crowdfunding campaign on the Netcapital platform. This campaign supports the next steps of...